Vaccine News and Research

Latest Vaccine News and Research

Whooping cough outbreak in Oklahoma

Oklahoma is witnessing an outbreak of whooping cough with more people falling ill. Health authorities are urging all people over 7 years of age to get vaccinated against the disease.

28 Nov 2010

Medicago, Genopole expand collaboration

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced an extension to its partnering agreement of July 2009 with Genopole®. Medicago and Genopole® will also work towards the creation a laboratory for research on vaccine and antibody targets of interest for France in terms of public health and biodefense.

26 Nov 2010

New WHO report highlights second-hand smoke danger

A report, a first of its kind, that assessed all deaths related to tobacco showed that secondhand smoke sickens millions and kills more than 600,000 people worldwide each year, including more than 165,000 children under 5.

25 Nov 2010

Looking back and moving forward: 100 years of Pneumococcal vaccination

"Since the introduction of smallpox vaccination by Sir Edward Jenner in 1796, it took 184 years until the WHO could declare the world free of smallpox. How long will it take to eliminate pneumococcus from the world?"

25 Nov 2010

Humanitarian benefits of rapid cholera vaccines deployment to at risk areas could be enormous

In the wake of devastating cholera outbreaks in refugee camps in earthquake-wracked Haiti, a group of leading experts from Harvard Medical School, George Washington University, and the International Vaccine Institute (IVI) have urged the United States to create an emergency stockpile of cholera vaccines for future humanitarian use.

25 Nov 2010

Specialists suggest U.S. should stockpile cholera vaccines for rapid deployment at disease outbreak

As the cholera epidemic in Haiti continues to rage, public health workers are focusing their efforts on treating the tens of thousands who have already been hospitalized with cholera-like symptoms and providing clean water and adequate sanitation to control the disease's spread.

25 Nov 2010

Dendritic cell vaccine induces immune responses in patients

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published this week in the journal Clinical Cancer Research, was used after surgical resection of metastatic tumors to try to prevent the growth of additional metastases.

25 Nov 2010

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

24 Nov 2010

Chlamydia alert for ‘Schoolies’

School leavers partying on the Gold Coast, Queensland may be at risk of serious sexually transmitted infections due to unprotected sex in the mood of celebration say health experts. Health specialists from the Queensland University of Technology (QUT) warn the youngsters in the 2010 Australian Chlamydia Conference in Brisbane.

24 Nov 2010

Important queries about PrEP, iPrEx trial for HIV infection

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.

24 Nov 2010

iPrEx trial shows reduction in new HIV infections

Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today.

24 Nov 2010

iPrEx oral PrEP study achieves major milestone in HIV prevention research

This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.

24 Nov 2010

Meningitis immunization program to launch in 3 African countries next month

At a press conference in London, health officials said that the anticipated roll-out of the MenAfriVac for meningitis in three African countries will start on Dec. 6, the BBC reports.

24 Nov 2010

Study estimates cost savings associated with global polio eradication; global post examines vaccination efforts in Africa

Research published in the November issue of the journal Vaccine found that a global campaign to eliminate polio could save between $40 billion and $50 billion over the next few decades if the crippling disease is wiped out within five years Bloomberg reports.

24 Nov 2010

Global initiative to eradicate polio could provide benefits of at least US$40-50 billion

A new study released today estimates that the global initiative to eradicate polio could provide net benefits of at least US$40-50 billion if transmission of wild polioviruses is interrupted within the next five years. The study provides the first rigorous evaluation of the benefits and costs of the Global Polio Eradication Initiative (GPEI)--the single largest project ever undertaken by the global health community. The study comes at a crucial time--following an outbreak in the Republic of the Congo and one in Tajikistan earlier this year--that highlight the risk of delays in finishing the job on polio.

23 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Pennsylvania's first reported flu-related death of 2010-11 flu season

The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season.

23 Nov 2010

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

23 Nov 2010

Soligenix receives U.S patent for modified immunogen in RiVax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office has granted patent #7,829,668, entitled Compositions and methods for modifying toxic effects of proteinaceous compounds.

22 Nov 2010

Is the decade long flirtation with vaccines over?

In light of increasing competition, saturation of key vaccine sectors and a lack of innovative late-stage vaccine candidates, maintaining the strong growth of the last decade will be a major challenge for the vaccines industry suggests independent market analyst, Datamonitor.

22 Nov 2010